Bailard, Inc. Mei Pharma, Inc. Transaction History

Bailard, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Jan 31, 2020	SELL	$1.65 - $2.48 $280,995 - $422,344	-170,300 Closed	0 $0
Q3 2019 Oct 18, 2019	SELL	$1.48 - $2.52 $553,064 - $941,703	-373,692 Reduced 68.69%	170,300 $286,000
Q2 2019 Jul 26, 2019	BUY	$2.45 - $3.32 $99,715 - $135,124	40,700 Added 8.09%	543,992 $1.36 Million
Q1 2019 Apr 24, 2019	BUY	$2.52 - $3.24 $307,440 - $395,280	122,000 Added 32.0%	503,292 $1.55 Million
Q4 2018 Feb 05, 2019	SELL	$1.92 - $4.1 $55,119 - $117,702	-28,708 Reduced 7.0%	381,292 $1.01 Million
Q3 2018 Nov 13, 2018	BUY	$3.39 - $4.61 $898,350 - $1.22 Million	265,000 Added 182.76%	410,000 $1.77 Million
Q2 2018 Aug 08, 2018	BUY	$1.89 - $4.95 $274,050 - $717,750	145,000 New	145,000 $571,000

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $356M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.